These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21514070)

  • 1. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma.
    Wang H; Li YX; Wang WH; Jin J; Dai JR; Wang SL; Liu YP; Song YW; Wang ZY; Liu QF; Fang H; Qi SN; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1115-21. PubMed ID: 21514070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer's ring: dosimetric analysis and clinical outcome.
    Bi XW; Li YX; Fang H; Jin J; Wang WH; Wang SL; Liu YP; Song YW; Ren H; Dai JR
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1086-93. PubMed ID: 24120822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
    Lu NN; Li YX; Wu RY; Zhang XM; Wang WH; Jin J; Song YW; Fang H; Ren H; Wang SL; Liu YP; Liu XF; Chen B; Dai JR; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):210-6. PubMed ID: 22436783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric comparison of helical tomotherapy, VMAT, fixed-field IMRT and 3D-conformal radiotherapy for stage I-II nasal natural killer T-cell lymphoma.
    Liu X; Huang E; Wang Y; He Y; Luo H; Zhong M; Qiu D; Li C; Yang H; He G; Zhou J; Jin F
    Radiat Oncol; 2017 Apr; 12(1):76. PubMed ID: 28449713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
    Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
    J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma.
    Li YX; Wang H; Jin J; Wang WH; Liu QF; Song YW; Wang ZY; Qi SN; Wang SL; Liu YP; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1809-15. PubMed ID: 21470789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of skin toxicity in patients with extranodal nasal-type natural killer/T-cell lymphoma after treatment with intensity-modulated radiotherapy and conventional radiotherapy.
    Gu Y; Yu H; Zuo X; Cao Q; Liang T; Ren Y; Yang H; Yang D
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S975-S979. PubMed ID: 30539832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results.
    Shen Q; Ma X; Hu W; Chen L; Huang J; Guo Y
    Radiat Oncol; 2013 Jun; 8():152. PubMed ID: 23800149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents.
    Wang ZY; Li YX; Wang WH; Jin J; Wang H; Song YW; Liu QF; Wang SL; Liu YP; Qi SN; Fang H; Liu XF; Yu ZH
    Blood; 2009 Nov; 114(23):4771-6. PubMed ID: 19812381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric evaluation and treatment outcome of intensity modulated radiation therapy after doxorubicin-based chemotherapy for primary mediastinal large B-cell lymphoma.
    Xu LM; Li YX; Fang H; Jin J; Wang WH; Wang SL; Liu YP; Song YW; Liu QF; Chen B; Qi SN; Ren H; Dai JR
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1289-95. PubMed ID: 23245279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of volumetric modulated arc therapy and sliding-window intensity-modulated radiotherapy in the treatment of Stage I-II nasal natural killer/T-cell lymphoma.
    Liu X; Yang Y; Jin F; He Y; Zhong M; Luo H; Qiu D; Li C; Yang H; He G; Wang Y
    Med Dosim; 2016; 41(1):42-6. PubMed ID: 26428072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: technique, early outcomes, and toxicity.
    Hoppe BS; Wolden SL; Zelefsky MJ; Mechalakos JG; Shah JP; Kraus DH; Lee N
    Head Neck; 2008 Jul; 30(7):925-32. PubMed ID: 18302261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
    Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
    J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.
    Yang CW; Wang CW; Hong RL; Tsai CL; Yao M; Tang JL; Lin CW; Cheng AL; Kuo SH
    J Radiat Res; 2017 Jan; 58(1):114-122. PubMed ID: 27534792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity Modulated Radiation Therapy for Early-Stage Primary Gastric Diffuse Large B-Cell Lymphoma: Dosimetric Analysis, Clinical Outcome, and Quality of Life.
    Liu X; Fang H; Tian Y; Wang WH; Song YW; Wang SL; Liu YP; He XH; Dong M; Ren H; Jin J; Li YX
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):712-20. PubMed ID: 27034178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of the Bolus in Intensity-Modulated Radiotherapy and Volumetric-Modulated Arc Therapy for Stage I-II Nasal Natural Killer/T-Cell Lymphoma.
    Liu X; Wang Y; Guo Q; Luo H; Luo Q; Li Q; Wu Z; Jin F
    Oncol Res Treat; 2020; 43(4):140-145. PubMed ID: 32018254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
    Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
    [No Abstract]   [Full Text] [Related]  

  • 20. Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy.
    Li YX; Liu QF; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Liu XF; Zhou LQ; Yu ZH
    Cancer; 2011 Nov; 117(22):5203-11. PubMed ID: 21523771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.